AXSOME THERAPEUTICS Insider Activity: What Investors Need to Know

🌥️Trending News

Investors in Axsome Therapeutics ($NASDAQ:AXSM) Inc AXSM need to know the latest insider activity in order to make informed decisions. Axsome Therapeutics is a biopharmaceutical company that focuses on developing novel therapies for central nervous system (CNS) disorders. Their mission is to bring meaningful advances in the treatment of CNS disorders and provide hope and improved quality of life to patients. With locations in New York City and RTP, North Carolina, they are dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of serious CNS disorders. Their research and development efforts are centered around the areas of pain, depression, agitation, and other cognitive impairment disorders.

Insider activity at Axsome Therapeutics Inc is an important indicator for investors as it can be seen as a signal of future performance. Therefore, investors should be aware of any new developments at the company, such as insider buying or selling of shares. Understanding how insiders are trading can help investors make more informed decisions when investing in the company.

Market Price

With so much insider activity taking place within the company, it is important for investors to be aware of what is going on. This activity can impact the stock price and potential investment opportunities, so investors should be aware of the current activity. The company also recently announced the addition of a new independent director to their board, indicating that there may be some positive changes coming in the future. Insiders have also sold shares, which could indicate that they believe the stock is currently overvalued or that they believe better opportunities exist elsewhere.

Overall, understanding insider activity of AXSOME THERAPEUTICS is essential to determining if the stock is a good buy or not. Investors should closely monitor the company’s activity to make sure they are informed of any potential changes. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Axsome Therapeutics. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Axsome Therapeutics. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Axsome Therapeutics. More…

Key Ratios Snapshot

Some of the financial key ratios for Axsome Therapeutics are shown below. More…

Analysis

GoodWhale conducted an analysis of AXSOME THERAPEUTICS‘s wellbeing and we found that according to Star Chart, AXSOME THERAPEUTICS is strong in asset and growth, but weak in dividend and profitability. Our evaluation has given AXSOME THERAPEUTICS a health score of 3/10, due to its cashflow and debt. This suggests that AXSOME THERAPEUTICS is less likely to ride out any crisis safely without the risk of bankruptcy. We have classified AXSOME THERAPEUTICS as ‘cheetah’, a type of company that has achieved high revenue or earnings growth, but is considered less stable due to lower profitability. Investors who are looking for high growth potential with some risk may be interested in this type of company. More…

Peers

The company’s lead product candidate, AXS-05, is in Phase III clinical development for treatment-resistant depression (TRD), and has completed Phase II clinical development for Alzheimer’s disease (AD) agitation. Provention Bio Inc, NGM Biopharmaceuticals Inc, Orphazyme AS are all companies focused on developing novel therapies for CNS disorders and are AXS-05’s main competitors in the market.

– Provention Bio Inc ($NASDAQ:PRVB)

Prevention Bio Inc is a clinical-stage biopharmaceutical company developing novel, best-in-class therapeutics for life-threatening infectious diseases with high unmet medical need. The company’s primary focus is on developing its lead product candidate, PB01, for the prevention and treatment of severe sepsis. PB01 is a first-in-class monoclonal antibody that targets a key protein involved in the body’s inflammatory response to infection. Prevention Bio is currently enrolling patients in a Phase 2 clinical trial of PB01 in patients with severe sepsis.

Prevention Bio’s market cap of $643.47 million and ROE of -80.87% reflect the company’s high potential and significant risk. Prevention Bio is a clinical-stage company, meaning its products are still in development and have not yet been approved for market. While the company’s lead product candidate, PB01, has shown promise in early clinical trials, it remains to be seen whether it will be safe and effective in larger trials and ultimately be approved for market. Given the significant risks associated with clinical-stage companies, investors are likely to require a higher return on their investment in Prevention Bio than in more established companies.

– NGM Biopharmaceuticals Inc ($NASDAQ:NGM)

NGM Biopharmaceuticals Inc is a clinical stage biopharmaceutical company. The company focuses on the discovery and development of novel therapeutic proteins for the treatment of serious diseases. NGM Biopharmaceuticals Inc has a market cap of 438.05M as of 2022, a Return on Equity of -28.16%. The company’s main products are in the areas of oncology, diabetes and obesity.

– Orphazyme AS ($OTCPK:OZYMF)

Orphazyme AS is a pharmaceutical company that focuses on the development of treatments for rare diseases. The company has a market cap of 5.56M as of 2022 and a Return on Equity of -845.21%. The company’s focus on rare diseases gives it a niche market, which allows it to charge higher prices for its products. However, the company’s high prices may limit its customer base and its ability to grow its business.

Summary

Investing in Axsome Therapeutics Inc. (AXSM) requires careful analysis of recent insider activity. Recently, there has been a decrease in insider selling compared to buying, signaling that insiders may be expecting positive developments for the company. On the same day of this activity, the stock price moved down slightly, indicating possible market sentiment changes for the company. Overall, investors should continue to monitor insider activity and market sentiment to help make informed decisions when investing in AXSM.